STAT3 and major depressive disorder: To investigate its involvement in the development of depression‐related neurological complications, the JAK‐STAT signaling pathway inhibitor (STAT3‐IN‐12) was administered via intraperitoneal injection in ICH mice and depression‐related behavioral tests were conducted on day 7 (Figure 6G,H).